Berlin: Bayer has received approval for elinzanetant from the U.S. Food and Drug Administration (FDA) as the dual neurokinin (NK) targeted therapy , neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, under the brand name Lynkuet for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) due to menopause.

Inhibition of Substance P and Neurokinin B through antagonism of NK1 and NK3 receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons with elinzanetant can modulate neuronal activity in the thermoregulation associated with hot flashes. The FDA approval is supported by data from three Phase III clinical studies (OASIS 1, OASIS 2 and OASIS 3) that evaluated the efficacy and safety of elinzanetant for the treatment of moder

See Full Page